All Stories

AstraZeneca culls a Lilly-partnered Alzheimer's drug alongside 2 other neuroscience meds in Q1 clear-out

AstraZeneca has axed three MedImmune legacy monoclonal antibody drugs from its neuroscience pipeline in a first-quarter clear-out.

Apr 29, 2025 - 12:23
 0
AstraZeneca culls a Lilly-partnered Alzheimer's drug alongside 2 other neuroscience meds in Q1 clear-out
AstraZeneca has axed three MedImmune legacy monoclonal antibody drugs from its neuroscience pipeline in a first-quarter clear-out.
Read More

Tags:

Previous Article

Lexus highlights its Centre of Excellence top performers

Next Article

China hits out at 'extreme selfishness' of tariffs

Related Posts

Tempus AI in line for $200M from AstraZeneca, Pathos deal to develop cancer model

Tempus AI in line for $200M from AstraZeneca, Pathos de...

Apr 23, 2025  0

Etiome emerges with $50M from Flagship Pioneering and goal of preempting disease

Etiome emerges with $50M from Flagship Pioneering and g...

Apr 24, 2025  0

Chinese CRO GemPharmatech expands in San Diego as industry weighs FDA's animal testing shift

Chinese CRO GemPharmatech expands in San Diego as indus...

Apr 21, 2025  0